

Josã© Marã-a Pego-Reigosa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8837831/publications.pdf>

Version: 2024-02-01

82
papers

4,384
citations

186265
28
h-index

114465
63
g-index

86
all docs

86
docs citations

86
times ranked

4537
citing authors

#	ARTICLE	IF	CITATIONS
1	Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1529-1550.	2.4	19
2	Analysis of the implementation of an innovative IT solution to improve waiting times, communication with primary care and efficiency in Rheumatology. <i>BMC Health Services Research</i> , 2022, 22, 60.	2.2	5
3	Central Role of Semaphorin 3B in a Serum-Induced Arthritis Model and Reduced Levels in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 972-983.	5.6	9
4	Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151946.	3.4	4
5	Monocytes and Macrophages in Spondyloarthritis: Functional Roles and Effects of Current Therapies. <i>Cells</i> , 2022, 11, 515.	4.1	15
6	Study of Plasma Anti-CD26 Autoantibody Levels in a Cohort of Treatment-Naïve Early Arthritis Patients. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2022, 70, 12.	2.3	2
7	Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study. <i>Rheumatology</i> , 2022, 62, 217-224.	1.9	1
8	Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study*. <i>ReumatologÃa ClÃnica (English)</i> Tj ETQq0 0.0,rgBT /Overlock 10	0.3	16
9	Medication persistence on biological therapies prescribed for the treatment of chronic inflammatory arthropathies: a real-world data study. <i>European Journal of Hospital Pharmacy</i> , 2021, 28, e47-e50.	1.1	4
10	Comorbidities (excluding lymphoma) in SjÃgren's syndrome. <i>Rheumatology</i> , 2021, 60, 2075-2084.	1.9	30
11	Contributions of the lupus register of the Spanish Society of Rheumatology (RELESSER) to the knowledge of systemic lupus erythematosus in Spain. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2021, 17, 245-249.	0.3	0
12	The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis. <i>Rheumatology</i> , 2021, 60, 60-72.	1.9	42
13	Late-onset versus early-onset systemic lupus: characteristics and outcome in a national multicentre register (RELESSER). <i>Rheumatology</i> , 2021, 60, 1793-1803.	1.9	23
14	OUP accepted manuscript. <i>Rheumatology</i> , 2021, 60, e455.	1.9	0
15	Calcineurin and Systemic Lupus Erythematosus: The Rationale for Using Calcineurin Inhibitors in the Treatment of Lupus Nephritis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1263.	4.1	16
16	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.9	37
17	Myo-Spain: Registro de pacientes con miopatÃa inflamatoria idiopÃtica de EspaÃa. <i>MetodologÃa. ReumatologÃa ClÃnica</i> , 2021, , .	0.5	0
18	What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. <i>Lupus Science and Medicine</i> , 2021, 8, e000506.	2.7	1

#	ARTICLE	IF	CITATIONS
19	Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?. <i>Rheumatology</i> , 2021, 60, 5329-5336.	1.9	4
20	Aportaciones del registro de lupus de la Sociedad EspaÃ±ola de ReumatologÃ­a (RELESSER) al conocimiento del lupus eritematoso sistÃ©mico en EspaÃ±a. <i>ReumatologÃ­a ClÃ­nica</i> , 2021, 17, 245-249.	0.5	0
21	Prevalencia de artrosis sintomÃ¡tica en EspaÃ±a: Estudio EPISER2016. <i>ReumatologÃ­a ClÃ­nica</i> , 2021, 17, 461-470.	0.5	20
22	Distinctive CD26 Expression on CD4 T-Cell Subsets. <i>Biomolecules</i> , 2021, 11, 1446.	4.0	3
23	Comment on: Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries? Reply. <i>Rheumatology</i> , 2021, 60, e120-e121.	1.9	1
24	Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables. <i>Rheumatology International</i> , 2021, , 1.	3.0	0
25	Direct costs in patients with chronic inflammatory arthropathies on biological therapy: a real-world data study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 736-745.	0.8	0
26	Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study. <i>RMD Open</i> , 2021, 7, e001925.	3.8	8
27	Bacteremia in Systemic Lupus Erythematosus in Patients from a Spanish Registry: Risk Factors, Clinical and Microbiological Characteristics, and Outcomes. <i>Journal of Rheumatology</i> , 2020, 47, 234-240.	2.0	19
28	Hormonal Dependence and Cancer in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 72, 216-224.	3.4	11
29	Hydroxychloroquine is associated with a lower risk of polyautoimmunity: data from the RELESSER Registry. <i>Rheumatology</i> , 2020, 59, 2043-2051.	1.9	10
30	Semaphorin4A-Plexin D1 Axis Induces Th2 and Th17 While Represses Th1 Skewing in an Autocrine Manner. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6965.	4.1	16
31	Blocking IL-17: A Promising Strategy in the Treatment of Systemic Rheumatic Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7100.	4.1	39
32	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.9	35
33	Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. <i>Lupus</i> , 2020, 29, 1556-1565.	1.6	19
34	Angiopoietin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9544.	4.1	8
35	Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 657-662.	3.4	5
36	Prevalence and factors associated with osteoporosis and fragility fractures in patients with primary SjÃ¶rgren syndrome. <i>Rheumatology International</i> , 2020, 40, 1259-1265.	3.0	4

#	ARTICLE	IF	CITATIONS
37	Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 988-990.	0.9	66
38	Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries?. <i>Rheumatology</i> , 2020, 59, 2556-2562.	1.9	32
39	Desarrollo de una aplicaci3n para tel3fonos m3viles (app) basada en la colaboraci3n Sociedad Espaola de Reumatolog3a/Sociedad Espaola de Medicina de Familia y Comunitaria para derivaci3n de enfermedades autoinmunes sist3micas. <i>Reumatolog3a Cl3nica</i> , 2020, 16, 373-377.	0.5	7
40	Biological therapy safety in chronic inflammatory arthropathy patients. <i>European Journal of Rheumatology</i> , 2020, 7, 53-59.	0.6	0
41	Valoraci3n del riesgo de fractura en poblaci3n general en Espaola mediante el algoritmo FRAX3: Estudio EPISER2016. <i>Medicina Cl3nica</i> , 2020, 154, 163-170.	0.6	1
42	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.9	759
43	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	5.6	1,098
44	How to investigate: Suspected systemic rheumatic diseases in patients presenting with muscle complaints. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101437.	3.3	3
45	Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. <i>BMJ Open</i> , 2019, 9, e028697.	1.9	15
46	Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1025-1029.	3.4	14
47	Prevalencia de enfermedades reum3ticas en poblaci3n adulta en Espaola (estudio EPISER 2016). <i>Objetivos y metodolog3a. Reumatolog3a Cl3nica</i> , 2019, 15, 90-96.	0.5	63
48	Content analysis of Twitter in relation to biological treatments for chronic inflammatory arthropathies: an exploratory study. <i>European Journal of Hospital Pharmacy</i> , 2019, 26, 124-128.	1.1	6
49	Pure Membranous Lupus Nephritis: Description of a Cohort of 150 Patients and Review of the Literature. <i>Reumatolog3a Cl3nica</i> , 2019, 15, 34-42.	0.5	6
50	Adherence to biological therapies in patients with chronic inflammatory arthropathies. <i>Farmacia Hospitalaria</i> , 2019, 43, 134-139.	0.6	3
51	Primary respiratory disease in patients with systemic lupus erythematosus: data from the Spanish rheumatology society lupus registry (RELESSER) cohort. <i>Arthritis Research and Therapy</i> , 2018, 20, 280.	3.5	40
52	Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2018, 20, 100.	3.5	102
53	Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 38-45.	3.4	117
54	Anti-CD26 autoantibodies are involved in rheumatoid arthritis and show potential clinical interest. <i>Clinical Biochemistry</i> , 2017, 50, 903-910.	1.9	13

#	ARTICLE	IF	CITATIONS
55	Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study. <i>Arthritis Care and Research</i> , 2017, 69, 38-45.	3.4	27
56	Juvenile- and adult-onset systemic lupus erythematosus: a comparative study in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 1047-1055.	0.8	14
57	Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER). <i>Medicine (United States)</i> , 2016, 95, e2891.	1.0	55
58	Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry. <i>Rheumatology</i> , 2016, 55, 1243-1250.	1.9	28
59	Clinical practice guidelines for systemic lupus erythematosus: Recommendations for general clinical management. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 413.e1-413.e14.	0.2	7
60	Cardiovascular Events in Systemic Lupus Erythematosus. <i>Medicine (United States)</i> , 2015, 94, e1183.	1.0	96
61	CD26 Expression on T Helper Populations and sCD26 Serum Levels in Patients with Rheumatoid Arthritis. <i>PLoS ONE</i> , 2015, 10, e0131992.	2.5	19
62	Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus. <i>Lupus</i> , 2015, 24, 720-729.	1.6	20
63	Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real-Life, International Systemic Lupus Erythematosus Cohort. <i>Arthritis Care and Research</i> , 2015, 67, 1180-1185.	3.4	125
64	Comprehensive Description of Clinical Characteristics of a Large Systemic Lupus Erythematosus Cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) With Emphasis on Complete Versus Incomplete Lupus Differences. <i>Medicine (United States)</i> , 2015, 94, e267.	1.0	48
65	Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review. <i>Rheumatology International</i> , 2015, 35, 1447-1459.	3.0	29
66	Identification of lymphoma predictors in patients with primary Sjögren's syndrome: a systematic literature review and meta-analysis. <i>Rheumatology International</i> , 2015, 35, 17-26.	3.0	100
67	Registro nacional de pacientes con lupus eritematoso sistémico de la Sociedad Española de Reumatología: objetivos y metodología. <i>Reumatología Clínica</i> , 2014, 10, 17-24.	0.5	55
68	Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 175-185.	3.4	101
69	Biological therapy for systemic vasculitis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 542-557.	3.4	41
70	National Registry of Patients With Systemic Lupus Erythematosus of the Spanish Society of Rheumatology: Objectives and Methodology. <i>Reumatología Clínica (English Edition)</i> , 2014, 10, 17-24.	0.3	11
71	Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en el lupus eritematoso sistémico. <i>Reumatología Clínica</i> , 2013, 9, 281-296.	0.5	31
72	SER Consensus Statement on the Use of Biologic Therapy for Systemic Lupus Erythematosus. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 281-296.	0.3	10

#	ARTICLE	IF	CITATIONS
73	Efficacy and Safety of Nonbiologic Immunosuppressants in the Treatment of Nonrenal Systemic Lupus Erythematosus: A Systematic Review. <i>Arthritis Care and Research</i> , 2013, 65, 1775-1785.	3.4	50
74	Interstitial Lung Disease Induced or Exacerbated by TNF-Targeted Therapies: Analysis of 122 Cases. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 256-264.	3.4	244
75	Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. <i>Rheumatology</i> , 2010, 49, 691-696.	1.9	29
76	Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. <i>Rheumatology</i> , 2010, 49, 960-971.	1.9	94
77	Respiratory manifestations of systemic lupus erythematosus: old and new concepts. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 469-480.	3.3	117
78	Autoimmune diseases. <i>Medicine</i> , 2008, 36, 279-283.	0.4	0
79	Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2008, 48, 573-575.	1.9	23
80	Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. <i>Rheumatology</i> , 2008, 47, 1498-1502.	1.9	132
81	Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 31-41.	4.1	14
82	Calcium pyrophosphate deposition disease mimicking polymyalgia rheumatica: A prospective followup study of predictive factors for this condition in patients presenting with polymyalgia symptoms. <i>Arthritis and Rheumatism</i> , 2005, 53, 931-938.	6.7	52